Objective: To determine the effects of dietary change on serum concentrations of insulin, glucose, IGF-I and IGFBP-3. Subjects: From among participants in a randomized clinical trial of men and women without a history of diabetes who were 35 years old or older and who had at least one histologically confirmed colorectal adenoma removed during a qualifying colonoscopy within the 6 months before randomization, 750 subjects were selected for this analysis. Methods: The authors analyzed fasting serum from 375 subjects with and 375 subjects without a recurrent polyp among participants in a randomized trial of a low-fat (20% of energy), high-fiber (18 g per 1000 kcals of energy intake) and high-fruit and -vegetable (5-8 servings per day) dietary intervention. Results: After 4 years of follow-up, IGF-I concentration in the intervention group (N ¼ 248) declined by 8.86 ng/ml (initial mean of 133 ng/ml) and 7.74 ng/ml (initial mean value of 139 ng/ml) in the non-intervention group (N ¼ 502). Based on an unpaired t-test, these declines were both statistically significant, but the difference between groups for the decline in IGF-I (1.12 ng/ml ((95% confidence interval, À3.24 to 5.48)) was not. After 4 years, concentrations of IGFBP-3, insulin and glucose were not statistically different from values at baseline, and there were no differences in these serum measures between the intervention and control groups. In analysis restricted to lean (body mass index o25 kg/m 2 ) subjects only, however, glucose concentrations in the intervention group decreased by 0.28 mmol/l, while they increased in the control group by 0.01 mmol/l (t-test for mean differences P ¼ 0.0003) over 4 years. Conclusions: A low-fat, high-fiber, high-fruit and -vegetable dietary intervention had minimal impact on serum concentrations of insulin, glucose, IGF-I and IGFBP-3 overall, but in lean subjects the intervention resulted in a significant reduction in serum glucose concentration.
Introduction
While it is well established that increased weight is associated with elevated fasting insulin levels, impaired insulin sensitivity and ultimately diabetes (Bray, 2004) , it is not clear to what extent dietary change per se, independent of its potential influence on weight change, will affect serum concentrations of insulin. A small number of prospective studies have shown that high-fiber, low-saturated or animal fat, and high unsaturated or vegetable fat diets are associated with reduced risk of type II diabetes (Parillo and Riccardi, 2004) suggesting they will also be associated with improved insulin response and glycemic control. Cross-sectional studies looking directly at the effects of diet on insulin found lowered insulin concentrations among those reporting higher whole-grain intake (McKeown et al., 2002; Liese et al., 2003) as well as increased prevalence of hyperglycemia and hyperinsulinemia (in men but not women) with a highfat, low-fiber food pattern compared to other food patterns in a Swedish diet and cancer study cohort (Wirfalt et al., 2001) . A number of intervention studies have been undertaken that reported the effects of changes in diet on fasting concentrations of insulin and glucose or on insulin sensitivity. However, many of these involve subjects who were obese (Pereira et al., 2002; Foster et al., 2003; Lindstrom et al., 2003; Johnston et al., 2004; Meckling et al., 2004; Stern et al., 2004) had impaired glucose tolerance (Swinburn et al., 2001; Lindstrom et al., 2003; Wolever and Mehling, 2003) , impaired insulin sensitivity (McAuley et al., 2002; Pereira et al., 2002) or diabetes (Garg et al., 1994; Chandalia et al., 2000; Tsihlias et al., 2000; Jenkins et al., 2002; Parker et al., 2002) at baseline. Results from 12 dietary intervention studies in normal-weight, healthy individuals were somewhat mixed with many, but not all, showing modest reductions in fasting glucose concentration after the intervention but little change in insulin. These studies, however, were generally small (only one study enrolled as many as 100 subjects, with over half enrolling fewer than 25), used interventions of brief duration (interventions were longer than 12 weeks in only two studies and never longer than 6 months) and frequently involved significant weight change (Fukagawa et al., 1990; Landin et al., 1992; Straznicky et al., 1999; Bisschop et al., 2001; Bouche et al., 2002; Miller et al., 2002; Hall et al., 2003; Juntunen et al., 2003; Kaaks et al., 2003; Ambring et al., 2004; Heald et al., 2004; Sloth et al., 2004) .
Energy restriction has been shown to reduce serum concentrations of IGF-I and IGFBP-3 either as the result of long-term fasting or severe protein-energy malnutrition (Thissen et al., 1994) . The determinants of variability in IGF-I and IGFBP-3 among people in normal conditions of energy availability are much less well established. In one of the few studies examining dietary correlates of IGF-I and IGFBP-3, Holmes et al. (2002b) found, in a cross-sectional analysis of US nurses, that IGF-I was marginally reduced with increasing dietary fat intake and IGFBP-3 was significantly lower, but they observed no associations for IGF-I or IGFBP-3 with either fruits, vegetables or fiber. By contrast, in a similar cross-sectional analysis from the Oxford component of the EPIC cohort, subjects following a vegan diet had markedly lower concentrations of IGF-I and unchanged levels of IGFBP-3 compared to subjects following a typical British diet containing meat and dairy products (Allen et al., 2002) . Also, in another cross-sectional analysis from subjects residing in Athens, Greece, serum concentrations of both IGF-I and IGFBP-3 showed significant correlations with dietary fat (positively) and carbohydrates (inversely) (Kaklamani et al., 1999) . In the only dietary intervention study we were able to identify investigating this question, Ngo and colleagues found that individuals following a high-fiber, high-fruit and -vegetable Pritikin-style diet saw dramatic declines in both IGF-I and IGFBP-3 concentrations both for short-(11 day) and long-term (14 year) adherents to the diet. These subjects were all severely obese at baseline, however, and experienced massive weight reduction (from an average body mass index (BMI) of 38.4 down to 21.5 kg/m 2 in the long-term subjects) during the course of the study. In order to provide additional insight into the potential role of diet in the regulation of these biochemical parameters, we investigated the effects of a 4-year, high-fiber, high-fruit and -vegetable, low-fat dietary intervention on serum concentrations of glucose, insulin, IGF-I and IGFBP-3 in a population with no history of diabetes and having an average BMI at baseline consistent with US norms. Given the earlier evidence, we hypothesized that this dietary intervention would result in decreased serum concentrations of all four parameters, but especially of insulin and glucose. We further hypothesized that adiposity (as measured by body mass index) at baseline would modified the effects of the dietary intervention.
Materials and methods

Study population
We selected the subjects for these analyses from individuals enrolled in the Polyp Prevention Trial (PPT), a multicentered randomized trial of a dietary intervention designed to reduce the rate of recurrence for colorectal polyps. Details of the complete PPT protocol appear elsewhere (Schatzkin et al., 2000) . Briefly, subjects were men and women without a history of diabetes who were 35 years old or older and who had had at least one histologically confirmed colorectal adenoma removed during a qualifying colonoscopy within the 6 months before randomization. A qualifying colonoscopy was one in which the cecum was visualized, all polyps were removed and the colon was adequately prepared. The participating clinical centers identified potential subjects through referrals by endoscopists or reviews of records from the endoscopy service. These methods identified 38 277 potential subjects, and 2079 of these enrolled in the study. Of those initially enrolled, 1905 completed the protocol. The protocol included follow-up colonoscopies at years 1 and 4 after randomization and dietary assessment plus a fasting venous blood specimen at the baseline, year 1, and year 4 clinic visits. Of these 1905 subjects, 754 (39.6%) had recurrent polyps identified during the interval between the 1 year and 4 year follow-up colonoscopy, and 125 of the 754 subjects with adenomas were identified during this interval to have advanced lesions (defined as having a maximal diameter of at least 1 cm or at least 25% villous elements or evidence of high-grade dysplasia including carcinoma).
In order to select a subset of the subjects who completed the protocol for insulin, glucose, IGF-I and IGFBP-3 assays, we first excluded subjects with no available serum from the baseline visit (T0) and then excluded all subjects, except those with an advanced adenoma, with only one stored serum vial at T0. For case subjects (those with a recurrent adenoma) remaining after these exclusions, we identified potential matches on age and gender among the non-case subjects. For each case subject we then randomly selected a matching subject from among these non-cases who were potential matches. This yielded 591 matched pairs. From these, we selected all 125 pairs that included a case with an advanced adenoma and then selected pairs of subjects from the remaining 466 pairs until we had reached our target sample size of 375 pairs (or 750 subjects in total).
Dietary intervention
Upon enrollment, subjects were randomized into a dietary intervention group or a non-intervention group. Subjects in the intervention group were given dietary targets aimed at achieving a low-fat (20% of energy), high-fiber (18 g per 1000 kcals of energy intake) and high-fruit and -vegetable (5-8 servings per day) diet. Intervention group members received extensive nutritional information and behavior modification counseling, and were assigned a nutritionist to counsel them and provide assessment. Non-interventiongroup subjects received general dietary guidance based on recommendations of the National Dairy Council, but no additional information, behavior-change assistance, or other nutritional support.
Blood draw
As described above, all subjects provided fasting venous blood samples from which serum was separated at the baseline, year 1 and year 4 clinic visits. The serum was then aliquotted into 2 ml polypropylene cryovials (Nalgene 50000020), and stored at À701C within 4 h from blood draw.
Analytic design
From each of the 750 subjects included in these analyses, we selected one vial of frozen serum at each of three time points: baseline/randomization (T0), year 1 follow-up visit (T1) and year 4 follow-up visit (T4). We shipped these from the NCI repository in Frederick, MD, to the Maine Center for Osteoporosis Research and Education in Bangor, ME, for IGF-I and IGFP-3 assays. We also selected a second vial from each of these subjects at each of the three time points for shipment to the Department of Laboratory Medicine at the NIH Clinical Center for insulin and glucose assays. We used a shipping protocol designed to insure none of the vials thawed in transit, and all vials arrived at the analytic laboratories frozen and in good condition.
Assays
Serum glucose concentrations were determined by the glucose oxidase method on the Hitachi 917 analyzer (Roche, Indianapolis, IN, USA). At 70 mg/dl, the glucose assay has a total imprecision of o1.5%. Serum insulin was measured by a two-site chemiluminescent immunoassay on the DPC 2000 analyzer (DPC, Los Angeles, CA, USA). At 167 pmol/l (24 uIU/ ml), the insulin assay has a total imprecision of o5%. This is a specific assay having no cross-reactivity with proinsulin. Serum IGF-I concentration was measured using the IGF-I (IGFBP-blocked) radio immunoassay manufactured by American Laboratory Products Company (ALPCO, Windham, NH, USA). The calculated sensitivity of the assay is 0.02 ng/ml. The cross-reactivity with IGF-II is small (o0.05%). Concentrations of IGFBP-3 in serum were measured using the 'Active' IGFBP-3 IRMA kit manufactured by Diagnostic Systems Laboratories, Inc. (DSL, Webster, TX, USA). The calculated sensitivity of the kit is 0.5 ng/ml. The kit uses a two-site immunoradiometric principle to measure nonglycosylated IGFBP-3 directly.
Values below assay detection limit
Assays for serum insulin concentration produced results for some samples that were below the detection limit of the assay (13.9 pmol/l or 2.0 mIU/ml). Thirty-seven of the values at baseline were below the detection limit, 34 at year 1 of follow-up, and 23 at year 4. In total, 70 subjects had a value below 13.9 pmol/l at some point in the study. For subjects with one or more measurements below the detection limit, we used two different approaches to impute a value for the missing data. In the first, we simply assigned all measurements below the detection limit the value of 13.8 pmol/l (1.99 mIU/ml). For the t-tests of differences between intervention and control groups, this was the only approach available. For the regression analyses (see below) we created complete data sets by using an imputation method that assigned a value for each missing measurement from the assumed insulin distribution identified using maximum likelihood parameter estimates, adapting an approach described by Helsel (1990) . First, we set an upper bound for missing values at the detection limit for the assay (that is, 13.9 pmol/l). Next we created a likelihood function based on insulin data from the non-intervention subjects as the product of the normal density function at the log-transformed value for the known measurements and the cumulative normal distribution function at the log-transformed bound for the missing measurements and determined the maximum likelihood estimates of the mean and variance. We then imputed a value for each missing measurement by randomly sampling from a log-normal distribution with the estimated mean and variance parameters, conditional on the imputed value being below the detection limit. We obtained estimates of associations between intervention status and insulin concentrations using the complete data set as described in the statistical analysis section below. To accommodate the additional random variation in the estimates induced by imputing exposure values, we repeated the imputation procedure ten times for each analysis, fitted the regression model ten times and combined the results according to Rubin (1987) using PROC MIANALYZE, SAS 8.0. Imputing 13.8 in the regression analyses rather than using the multiple imputation methods described above did not materially affect the results (data not shown).
Statistical analyses
We used two statistical approaches to test the effect of the dietary intervention on serum concentrations of insulin, glucose, IGF-I and IGFBP-3.
First we compared mean differences (T1-T0, T4-T0 and T4-T1) between intervention group and non-intervention group on the four parameters using unpaired t-tests.
Second, we used patient-level data directly (that is, not the differences) to analyze the observations from the three time points (T0, T1 and T4) separately. To do this we fit longitudinal regression models to the four serum measures. With one of the four serum measures as the outcome variable in these regression models, we calculated a parameter estimate for the intervention group assignment indicator variable (coded 0 for control group and 1 for intervention group) adjusting for gender, age, race and clinical center (PROC GENMOD, SAS 8.0). We assumed an equi-correlated working correlation matrix (that is, equal correlation among the observations from different time points). In these models, the parameter estimate for the main effect of time indicated how the concentration of the serum analyte changed over the follow-up period, and the parameter estimate for the interaction term between time and intervention group indicated the difference in the change over time between the two groups. In this parameterization, a statistically significant estimate for the interaction term would be evidence of a treatment effect on the concentration of the serum analyte.
For the glucose analyses, we excluded one subject with an unusually high serum concentration at baseline (greater than 55.5 mmol/l or 1000 mg/dl). Inclusion of this subject made no material difference in the results.
Results
Characteristics of the study sub-sample Baseline characteristics by intervention status of the PPT subjects we selected for this study appear in Table 1 . A slightly greater proportion of subjects in the non-intervention group were male compared to those in the intervention group, and not surprisingly therefore, the subjects in the non-intervention group also had a higher average daily energy intake as well. Other than on gender and energy intake, there were no notable differences between intervention and non-intervention subjects in our sub-sample of the PPT study population. 
Success of dietary intervention
Based on changes in reported dietary intake and in blood parameters (e.g., serum total carotenoids) in the overall PPT sample, the intervention group appeared to be largely successful in achieving the dietary objectives (Schatzkin et al., 2000) . Table 2 presents data indicating how a number of dietary and diet-related parameters changed over the course of the intervention period for subjects selected for the serum analyses. Based on self-reports of dietary practice, the intervention group was highly successful in adopting the recommended high-fiber, high-fruit and -vegetable, low-fat diet. In the intervention group, the percent of calories from fat decreased from 35.0 to 22.7, fiber increased from 18.9 to 33.6 g/day, vegetable intake rose from 271.8 to 454.3 g/day, and fruit intake more than doubled going from 168.3 to 357.5 g/day. Whole grains, legumes, cruciferous vegetables, and folate from diet saw similar increases. By contrast, the subjects in the non-intervention group saw modest, nonsignificant differences between baseline and year 4 of followup on these dietary variables. Total energy intake remained constant in the two groups, but the intervention group and the non-intervention group achieved different results with respect to weight change; the intervention group went down slightly in weight whereas the non-intervention group went up. Yet while the difference in the weight change between the two groups was statistically significant, the absolute difference in average weight change between them at year 4 of follow-up was only 0.9 kg. Table 3 presents the results from the comparison of grouplevel mean changes in each of the four blood parameters over the course of the PPT follow-up period. There were no significant changes from T0 to T1 or from T0 to T4 for insulin or glucose, nor were there any significant differences between the changes in mean concentrations of these analytes in the intervention compared to the non-intervention group. In the case of IGFBP-3, there was a slight decrease in concentration across the intervention period, but this did not reach statistical significance. For IGF-I, the decrease in concentration between T0 and T4 in both the intervention and the non-intervention groups was significant. For neither IGF-I nor IGFBP-3, however, were the changes in mean concentration over the follow-up period significantly different (or even suggestively different) between intervention and non-intervention-group subjects. Thus while concentrations of these two serum measures declined with time, the changes were unrelated to the intervention. A somewhat different picture resulted when we performed a stratified analysis based on BMI at baseline (Table 4) . In analyses restricted to subjects with a BMI of 25 kg/m 2 or above, we again saw no effect of the intervention, but among those with a BMI less than 25, while there was no effect of the intervention on IGF-I, IGFBP-3 and insulin, we did see a highly significant divergence in the fasting glucose concentrations. By the fourth year of follow up, glucose had decreased for the lean subjects in the intervention group by 0.282 mmol/l (95% confidence interval (CI) 0.506-0.057 mmol/l decrease) compared to an increase of 0.099 mmol/l (95% CI 0.008-0.192 mmol/l increase) in the non-intervention subjects (P for t-test of difference between mean differences ¼ 0.0003). Further stratification of the subjects with BMI values above 25 resulted in similar null results for all substrata as those we observed for all of these subjects combined. The absolute difference in the change is calculated as (T4-T0 for control) -(T4-T0 for intervention).
Intervention effects
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The results from the regression analyses were largely consistent with the results from the t-tests comparing the differences of the changes in mean concentration between intervention and non-intervention groups (Table 5 ). The negative sign on the parameter estimate for time in the IGF-I and IGFBP-3 models indicates a decrease in concentration across the follow-up period for each of these analytes (with the decrease being highly significant for IGF-1, Po0.0001). But for both of these, the parameter estimate for the interaction terms was non-significant indicating no difference between intervention and non-intervention groups in the rate of decrease for either analyte. For insulin, a parameter estimate of 0.0257 (P ¼ 0.02) for the main effect of time indicated that overall insulin concentrations did rise slightly over time in the study population, but the nonsignificant parameter estimate for the interaction term between time and intervention group indicated that the change in insulin concentration was not different between intervention and non-intervention subjects (that is, there was no treatment effect). The regression results also indicate that fasting glucose concentrations did not change significantly with time, although there was a marginally significant trend for the intervention group to show a greater decrease in concentration than the non-intervention group. After stratifying on BMI at baseline, however, we again observed that among the lean subjects, but not among the overweight subjects, the intervention resulted in significantly greater reductions in glucose concentrations over the follow-up period when compared against changes in the non-intervention subjects (Table 5) .
For each of the analytical approaches described above, we also considered the homeostasis model assessment index, an indicator of insulin resistance defined as the product of fasting insulin and fasting glucose all divided by 22.5, as an outcome, but in no case did we observe significant differences between intervention and control groups during the course of the follow-up period (data not shown).
Since the selection of subjects for these assays was based on recurrence status (for each subject we selected with a recurrent adenoma during the follow-up period, we identified an age and gender-matched subject with no adenoma in the follow-up period), and since recurrence may directly affect the serum concentration of these analytes, we also did an analysis stratified on recurrence status. In no case, however, was there a material difference in the results between those with and those without recurrent adenomas (data not shown).
Discussion
In this randomized clinical trial of a dietary intervention that was low in fat and high in fruits, vegetables and fiber, we saw no evidence that large-scale dietary change of this type had any effect on serum concentrations of insulin, glucose, IGF-I or IGFBP-3 over a 4-year follow-up period in the overall study population. For insulin and glucose, we observed no change in serum concentrations in either group over the course of the study. For IGF-I and IGFBP-3, serum concentrations did decrease with time (especially in IGF-I), but this was not an unexpected result as it is well established that their concentrations naturally decline with age after reaching peak levels in late adolescence (Juul, 2003) . The important observation in this case was that the dietary intervention did not affect the relative rate of decline in IGF-I or IGFBP-3. 
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The results became more complicated when we considered the potential mediating effect of BMI on these serum concentrations. Overweight and obesity, and especially central adiposity, have been strongly implicated as risk factors for insulin resistance, elevated fasting glucose and type II diabetes (Grundy, 2004) . As such, if the role of diet in the long-term regulation of fasting insulin and glucose concentrations were through its contribution to weight gain only, any dietary intervention that failed to have substantial effect on weight would also fail to affect these parameters. The dietary intervention in the PPT was not designed with an explicit weight-loss intention, yet as shown in Table 2 , weight did show a statistically significant change between the intervention and non-intervention groups by the end of follow-up. However, this difference in weight, while statistically significant, may not have been clinically important with respect to modulating obesity-related mediators of fasting insulin and glucose concentrations. The change in weight was relatively modest between the two groups, and in fact, for both groups, the change in weight from baseline was not significant. Only the relative change from baseline between the groups was, and this was only 0.9 kg over 4 years of follow-up.
Thus, it is possible that the intervention could have affected these parameters but that its impact was insufficient to counter the dominant effects of overweight and obesity in this study population. Given that the mean BMI values at baseline for the intervention and non-intervention groups, respectively, were 27.5 and 27.7 kg/m 2 , the contribution of excess body weight to insulin and glucose levels may have Table 4 Insulin, glucose, IGF-I and IGFBP-3 concentrations at baseline (T0), and changes after 1 (T1-T0) and 4 years (T4-T0) of follow-up in the intervention vs control groups in the PPT, after stratifying on BMI Effects of a dietary intervention on insulin, glucose, IGF-I and IGFBP-3 A Flood et al 
Abbreviations: PPT, Polyp Prevention Trial; BMI, body mass index; CI, cumulative interval. a Parameter estimates are for log-transformed values of outcome variables. b All models also included terms for the intervention group main effect, gender, ethnicity, age and study center. The parameter estimate for the treatment group main effect simply describes the difference between the two treatment groups at baseline; the interaction term between treatment group and time describes how the change over time in the outcome variable (as described by the parameter estimate listed in the table for main effect of time) is modified by treatment group status.
Effects of a dietary intervention on insulin, glucose, IGF-I and IGFBP-3 A Flood et al overwhelmed any more modest effect the change in diet may have produced. If this were true, the effect of the diet change may have been only observable in those subjects who were comparatively lean at baseline. Interestingly, if we restricted our analysis to the subjects with BMI values less than 25, the WHO cutoff for overweight and obesity, mean serum concentration of glucose (but not the other three parameters), did decrease significantly in the intervention group, while it increased significantly in the non-intervention group. This result is consistent with this notion that the intervention was not sufficient to overcome the dominant effects of overweight and obesity, but did result in lowered serum concentrations of glucose for those in a more 'healthy' state at baseline. If we stratified on either glucose or insulin, we observed no changes in serum concentration of glucose among those above the median values at baseline, but we did see significant reductions in glucose in the intervention group compared to the non-intervention group for those below the median on these measures at baseline (data not shown).
In contrast to the glucose values, however, the insulin results did not show any evidence of change after stratification. It is possible that glucose is simply more sensitive to dietary change in general than is insulin. In a wide range of intervention studies testing the effects of a variety of dietary interventions (including low-fat diets, low-glycemic index diets, the DASH diet, Mediterranean diet, high-fiber diets and diets that substitute mono-unsaturated fat in place of saturated fat), it was frequently the case that if the investigators observed any changes, they observed decreases in glucose concentration but no change in insulin concentration (Fukagawa et al., 1990; Landin et al., 1992; Straznicky et al., 1999; Bisschop et al., 2001; Bouche et al., 2002; Miller et al., 2002; Hall et al., 2003; Juntunen et al., 2003; Kaaks et al., 2003; Ambring et al., 2004; Heald et al., 2004; Sloth et al., 2004) . Our results are consistent with these findings.
It is also important to note, however, that there were substantial differences in the baseline concentrations of insulin and glucose that may help explain why we observed an effect for one parameter and not the other. Our sample had a mean insulin value at baseline of 56.5 and 58.1 pmol/l in the intervention and non-intervention groups, respectively. These figures were both on the low end of the normal range (34.7-138.9 pmol/l) (Larsen et al., 2003) suggesting there was little room for improvement on that parameter. By contrast, mean glucose concentrations in our sample, at 5.43 and 5.19 mmol/l in the intervention and non-intervention groups, respectively, were somewhat above the mid-point of the normal range (4.16-6.38 mmol/l) (Larsen et al., 2003) . Among the lean subjects, the mean glucose concentration was lower than in the overweight subjects (5.06 and 4.86 mmol/l in the intervention and non-intervention groups, respectively), but they were still near the middle of the normally observed distribution of glucose values. This contrasts with the insulin values. Among the lean subjects in the PPT, insulin was at the very bottom of the normally observed range (33.4 and 40.4 pmol/l for intervention and non-intervention groups, respectively). Thus while serum insulin in the PPT sample was already near its normally observed minimum value, substantial room existed for decrease in the glucose levels. It may be reasonable to speculate that in a lean population with elevated fasting insulin concentrations, this type of dietary intervention could generate decreases in those values as well.
Interestingly, in obese subjects, serum concentrations of IGF-I are generally no different from those in non-obese subjects (Juul et al., 1994; Travers et al., 1998; Lukanova et al., 2001 Lukanova et al., , 2002 Holmes et al., 2002a; Allen et al., 2003) . By contrast, IGFBP-1 is acutely responsive to levels of insulin (Sandhu et al., 2002) , and since insulin levels are typically elevated in obesity, IGFBP-1 is generally lower as well (Argiles and Lopez-Soriano, 2001; Maccario et al., 2001; Sandhu et al., 2002; Allen et al., 2003) . This suggests that while absolute levels of IGF-I may not differ between lean and obese individuals, unbound or bio-available IGF-1 is higher among the obese. Again, however, subjects in the PPT generally had insulin levels that were not elevated, and weight did not change appreciably in the intervention group. Thus we could not have observed any obesity-associated changes in insulin levels. Insulin concentrations in this study did not change with time in either group, so concentrations of IGFBP-1, and hence free IGF-I, would be unlikely to change as well (we had no data on IGFBP-I concentrations). Without the ability of the dietary intervention to affect weight, these data suggest there is no reason to expect that this type of diet will affect either IGF-I or 'free' IGF-I through changes in serum insulin concentrations in a population with low baseline levels of insulin.
The failure of the intervention to affect the concentrations of glucose in overweight and obese subjects plus insulin, IGF-I and IGFBP-3 in all subjects occurred despite the apparent success of the study subjects in adopting the dietary changes recommended by the PPT protocol. The data do indicate what appear to be large-scale changes in dietary habits in the intervention group, while the non-intervention group showed almost no variation from baseline diet at the end of the follow-up period. It is possible that misreporting of diet by subjects in the intervention group resulted in overstating the actual changes in their dietary practices, but the differences were so large (subjects in the intervention group reported that collectively they were consuming almost half as much dietary fat and twice as much fiber, fruits and vegetables as they reported at baseline) that it seems unlikely that at least some significant changes in dietary practice did not occur. Furthermore, we did observe an effect of the intervention on more objective measures of intake such as fasting glucose in lean subjects as well as weight change and serum total carotenoids in the overall PPT population (Schatzkin et al., 2000) . This provides evidence that the intervention, as adopted, resulted in measurable differences in related biological outcome variables and thus had the Effects of a dietary intervention on insulin, glucose, IGF-I and IGFBP-3 A Flood et al potential to yield differences in other clinical outcomes. Therefore failure to observe the effects of the intervention on the remaining blood parameters suggests they may not be related to these types of dietary changes, at least in the short run. In summary, this study provided no evidence that adopting a low-fat, high-fiber, high-fruit and -vegetable diet that did not result in weight change will result in improved levels of insulin, glucose, IGF-I and IGFBP-3 if we looked at the study population as a whole. On the other hand, we also saw no evidence that this comparatively high carbohydrate, low-fat diet would in any way lead to increases in serum concentrations of insulin, glucose, IGF-I, or IGFBP-3 suggesting therefore that it is unlikely to increase risk of cancer or insulin resistance, diabetes, and related cardiovascular outcomes. Furthermore our results showed that while a change in diet was not of benefit to those in the overweight or obese categories, changing to a low-fat, high-fiber, high-fruit and -vegetable diet did lower fasting concentrations of serum glucose among the lean subjects. This result suggests a potential further reduction in their already low risk of developing insulin resistance, diabetes, cardiovascular disease and cancer. The dietary intervention in the PPT, while it did result in a substantial change in macronutrient composition, did not result in significant weight loss compared to baseline, and the dominant effects of obesity may have obscured any benefit of the intervention among the overweight subjects in our study. It is important to note that the key variable for weight loss appears not to be dietary macronutrient composition so much as energy balance (Willett, 2002) . Thus our study was not designed to address this question. Nonetheless, it did show an effect of diet composition on blood glucose in lean subjects. Additional studies of how diet and physical activity interventions shown to reduce weight affect these biochemical parameters would be of great value. Unfortunately, there are no examples of dietary interventions that have been demonstrated reliably to result in long-term weight reduction.
